Boardroom Alpha
Start trial
10-K primary document
NUTX · Annual Report (Form 10-K) · Filed March 5, 2026

Nutex Health Inc — 10-K exhibit

ex47-amendmentno1totheamen.htm
Nutex Health Inc on Boardroom Alpha
Document

AMENDMENT NO. 1
TO
THE AMENDED AND RESTATED NUTEX HEALTH INC. 2023 EQUITY INCENTIVE PLAN
THIS AMENDMENT NO. 1 TO THE AMENDED AND RESTATED 2023 NUTEX HEALTH INC. EQUITY INCENTIVE PLAN (this “Amendment”) is made effective July 14, 2025, upon the approval of the stockholders of Nutex Health Inc. (“Nutex Health” or “the Company”) of this Amendment (the “Effective Date”). All capitalized terms used but not otherwise defined herein shall have the respective meanings ascribed to such terms in the Plan (as defined below).
RECITALS
WHEREAS, the Company maintains the Amended and Restated 2023 Nutex Health Inc. Equity Incentive Plan (the “Plan”).
WHEREAS, pursuant to the Plan, the Board of Directors of the Company (the “Board”) has the authority to amend the Plan from time to time; and
WHEREAS, the Board approved this Amendment on May 16, 2025.
NOW, THEREFORE, BE IT RESOLVED, that the Plan is hereby amended as follows, effective as of the Effective Date:
AMENDMENT
1.
Section 11.25 of the Plan is hereby amended in its entirety to read as follows:
“Overall Share Limit” means the sum of (a) 1,106,620 Shares, and (b) an annual increase on the first day of each calendar year beginning on and including January 1, 2026 and ending on and including January 1, 2033 equal to the lesser of (i) 5% of the aggregate number of shares of Common Stock outstanding on the final day of the immediately preceding calendar year and (ii) such smaller number of Shares as is determined by the Board.
2.
This Amendment shall be and hereby is incorporated into and forms a part of the Plan.

3.
Except as expressly provided herein, all terms and conditions of the Plan shall remain in full force and effect.


Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer